The underlying diagnosis 
Anticoagulated patients who present with acute gastrointestinal haemorrhage pose great therapeutic challenges. Most are being anticoagulated for life-threatening conditions and the clinician is faced with the difficult choice of reversing anticoagulation and risking thrombo-embolic consequences or continuing anticoagulation and risking exanguination. Bleeding has been recognised as the major treatment-limiting complication of anticoagulant treatment, and the risk of bleeding complications has been the subject of a number of studies.' The risk of bleeding is influenced by the intensity of anticoagulation therapy,'2I67 the patient's underlying disorder,' 5 comorbid conditions,'25 and the concomitant use of aspirin.89 Despite various advances in monitoring these patients,'0" bleeding related to anticoagulation treatment is frequent, and major bleeding occurs in up to 20%.' 4 5 Previous series have shown that most anticoagulated patients who present with gastrointestinal bleeding do so from mucosal disease'2 13 (2) subjects were managed by the same teams in an identical manner. Patients (anticoagulated and control) found at endoscopy to have either active haemorrhage from a peptic ulcer bed or a protuberant vessel that was not bleeding received endoscopic treatment. This comprised injection with 2-10 ml of 1:100 000 adrenaline plus 0 5-2 ml of 5% ethanolamine oleate or applications of the heater probe (Keymed Ltd, UK). The details of the technique of endoscopy therapy are described elsewhere.'516 One of two experienced endoscopists (CPC or CR) was entirely responsible for treatment. Rebleeding (defined as fresh haematemesis or melaena associated with the sudden development of shock), operation rates, transfusion requirements, duration of hospital admission, and 30 day mortality were recorded.
Warfarin was restarted five days after bleeding had stopped in patients in whom it was considered essential.
Differences in outcome were analysed using the X2 test and Student's t test as appropriate.
The study was approved by the Ethics of Medicine and Oncology Committee of the Lothian Health Board. When possible written consent was obtained from each patient, otherwise permission was obtained from a relative or, in rare circumstances, retrospectively.
Results

PATIENT CHARACTERISTICS
The median age ofthe 52 anticoagulated patients was 70 years (range 51-84); 32 were men. The indications for anticoagulation were valvular heart disease (27 patients), venous thromboembolic disease (13) , peripheral arterial grafts (3), coronary artery disease (4), cerebrovascular disease (2), recurrent atrial fibrillation (2) , and left ventricular aneurysmectomy (1). Only six patients had had recent dyspeptic symptoms, although seven had a previous history of peptic ulcer disease.
A bleeding source was identified in 43 (83%) patients (Figure) . Twenty three patients were anticoagulated within the therapeutic range at presentation (INR 2-5-3 5 for prosthetic heart valves, 2-0-3-0 for other indications). A bleeding source was identified in 19 (83%) of these. Twenty nine patients were anticoagulated beyond the therapeutic range and a source of Table I . The two groups were well matched for known risk factors except for the mean haemoglobin concentration on admission to hospital, which was significantly lower in the anticoagulated group.
Endoscopic treatment was possible in 22 patients taking warfarin and in 47 controls. The failures were a consequence of inaccessibility of the ulcer to injection or the heater probe. The outcome of treatment is presented in Table II . Uncontrolled haemorrhage or rebleeding were relatively infrequent in both groups and a similar proportion required emergency surgery. Transfusion requirements and hospital stay tended to be slightly greater in the anticoagulated patients, but this did not achieve statistical significance.
There were no significant complications after endoscopic treatment in any patient. Two patients from the control group died from postoperative complications of emergency surgery.
RE-ANTICOAGULATION
Warfarin was restarted in 28 patients (54%) five days after the bleeding had stopped. Patients with peptic ulcer received long term maintainance treatment with H2 receptor antagonists. Patients were followed for a median period of 9 5 months (range 4-46 months) and two rebled from gastric erosions after three and seven months respectively. Five patients died during the follow up period -the two gastric cancer patients, one patient who developed disseminated ovarian carcinoma, and two patients with cerebral haemorrhage (both were taking warfarin at the time).
Discussion
This study confirms that most anticoagulated patients who present with severe acute gastrointestinal bleeding have underlying mucosal disease. Endoscopy is therefore mandatory in these patients.
Patients presented with gastrointestinal bleeding an extremely variable time after beginning warfarin, and the duration ofanticoagulation did not influence the chances of discovering a bleeding source. Indeed, 13 patients presented within three weeks of starting warfarin and a cause for bleeding was found in most (85%). In contrast, 12 had received anticoagulants for more than 10 years and eight of-these were also found to have an upper gastrointestinal bleeding source.
The degree of anticoagulation did not seem to be related to the frequency of identifying a bleeding site. It has been suggested that bleeding that occurs when the INR is below 3 0 is frequently associated with an obvious underlying cause.2 17 We found that patients who were over-anticoagulated had also usually bled from a mucosal lesion and we would stress that this group of patients should be as assiduously investigated as patients anticoagulated within the therapeutic range or indeed patients not receiving warfarin.
The commonest cause of bleeding in anticoagulated patients was peptic ulcer, and this study shows that patients who have major endoscopic stigmata of bleeding can safely undergo endoscopic treatment by injection or heater probe treatment. The outcome in these patients is good, even when anticoagulation is incompletely reversed. Treated patients in this series had an INR of 1-5-2-5 and yet the frequency of rebleeding and operation rates were low and similar to those in patients not receiving anticoagulation. 16 Anticoagulated patients tended to receive more blood transfusions and to be in hospital for longer than those who have not been anticoagulated, but this is probably because of comorbid diseases rather than more severe bleeding. There were no deaths in the bleeding ulcer patients in the warfarin group, while two (4%) of those not on warfarin died. After endoscopic treatment, continued antigoaculation seems safe, although we believe it wise to ensure ulcer healing by endoscopic means and to recommend long term maintainance drug treatment in this group.
